氯吡格雷联合依达拉奉右莰醇对急性脑梗死患者的疗效观察

doi:10.3760/cma.j.issn.1007-1245.2023.09.022

摘要/Abstract

摘要：

目的　探讨氯吡格雷联合依达拉奉右莰醇对急性脑梗死（ACI）患者的临床效果。方法　本研究为随机对照试验，选取2020年7月至2022年6月湘乡市人民医院收治的124例ACI患者，采用随机数字表法分为两组，各62例。对照组男36例、女26例，年龄（57.47±4.25）岁；观察组男33例、女29例，年龄（58.23±4.45）岁。两组患者常规支持治疗后，对照组给予氯吡格雷治疗，观察组给予氯吡格雷联合依达拉奉右莰醇治疗，治疗周期为2周。比较两组患者治疗前后血清炎症因子［超敏C反应蛋白（hs-CRP）、正五聚蛋白3（PTX3）、脂蛋白相关磷脂酶A2（Lp-PLA2）］、血流动力学指标［阻力指数（RI）、收缩期峰值血流速度（Vmax）、平均血流速度（Vmean）］、氧化应激指标［超氧化物歧化酶（SOD）、活性氧簇（ROS）、丙二醛（MDA）］、神经功能指标［神经元将异性烯醇化酶（NSE）、脑源性神经营养因子（BDNF）］、神经功能缺损程度、步行能力及日常生活能力等变化情况，并评估两组患者临床疗效及不良反应。采用t检验、χ²检验。结果　治疗后，观察组治疗总有效率为91.94%（57/62），高于对照组75.81%（47/62），差异有统计学意义（χ²=5.962，P=0.015）。治疗后，观察组血清hs-CRP ［（7.47±2.34）mg/L］、PTX3 ［（1.97±0.88）ng/L］、Lp-PLA2 ［（6.64±1.04）μg/L］、SOD ［（123.38±14.62）U/mg］、ROS ［（502.42±49.88）μmol/L］、MDA ［（40.12±5.02）μmol/L］、NSE ［（9.76±1.22）μg/L］、RI ［（0.67±0.08）］、美国国立卫生研究院卒中量表（NIHSS）评分［（7.28±0.43）分］、步行能力评分［（1.77±0.12）分］均低于对照组［（10.12±3.32）mg/L、（2.64±1.25）ng/L、（8.52±1.22）μg/L、（147.65±16.26）U/mg、（557.39±52.34）μmol/L、（46.34±5.24）μmol/L、（13.55±2.34）μg/L、（0.78±0.12）、（9.12±0.54）分、（2.44±0.17）分］，Vmean ［（62.82±5.47）cm/s］、Vmax水平［（87.94±9.78）cm/s］、BDNF ［（6.64±0.87）μg/L］、BI ［（69.64±7.14）分］均高于对照组［（58.62±5.34）cm/s、（84.14±8.66）cm/s、（5.03±0.82）μg/L、（62.38±6.72）分］，差异均有统计学意义（均P<0.05）。结论　氯吡格雷联合依达拉奉右莰醇治疗ACI疗效更好，可有效抑制炎性反应，清除氧自由基，从而改善脑内血流的流动，快速恢复缺血半暗带区血流供应，有助于神经功能恢复，增强自理能力，并且安全性较高。

关键词:

急性脑梗死, 依达拉奉右莰醇, 氯吡格雷, 炎症因子, 血流动力学, 氧化应激

Abstract:

Objective　To investigate the clinical effect of clopidogrel combined with edaravone dexamphetamine in the treatment of acute cerebral infarction (ACI). Methods　It was a randomized controlled trial. A total of 124 ACI patients admitted to The People's Hospital of Xiangxiang from July 2020 to June 2022 were selected, and were divided into two groups by the random number table method with 62 cases in each group. In the control group, there were 36 males and 26 females, aged (57.47±4.25) years; in the observation group, there were 33 males and 29 females, aged (58.23±4.45) years. After routine supportive treatment, the control group was given clopidogrel, and the observation group was given clopidogrel combined with edaravone dexamphetamine, for a period of 2 weeks. The serum inflammatory factors [hypersensitive C-reactive protein (hs-CRP), pentraxin 3 (PTX3), and lipoprotein-associated phospholipase A2 (Lp-PLA2)], hemodynamic indexes [resistance index (RI), peak systolic blood velocity (Vmax), and mean blood velocity (Vmean)], oxidative stress indexes [superoxide dismutase (SOD), reactive oxygen species (ROS), and malondialdehyde (MDA)], neurological function indicators [neuron-specific enolase (NSE) and brain-derived neurotrophic factor (BDNF)], degrees of neurological impairment, walking ability, and ability of daily living were compared between the two groups before and after treatment. The clinical efficacies and adverse reactions of the two groups were evaluated. t test and χ² test were used. Results　After treatment, the total effective rate of the observation group was 91.94% (57/62), which was higher than that of the control group [75.81% (47/62)], with a statistically significant difference (χ²=5.962, P=0.015). The levels of serum hs-CRP [(7.47±2.34) mg/L], PTX3 [(1.97±0.88) ng/L], Lp-PLA2 [(6.64±1.04) μg/L], SOD [(123.38±14.62) U/mg], ROS [(502.42±49.88) μmol/L], MDA [(40.12±5.02) μmol/L], and NSE [(9.76±1.22) μg/L], RI [(0.67±0.08)], score of National Institutes of Health Stroke Scale (NIHSS) [(7.28±0.43) points], and walking ability score [(1.77±0.12) points] in the observation group were lower than those in the control group [(10.12±3.32) mg/L, (2.64±1.25) ng/L, (8.52±1.22) μg/L, (147.65±16.26) U/mg, (557.39±52.34) μmol/L, (46.34±5.24) μmol/L, (13.55±2.34) μg/L, (0.78±0.12), (9.12±0.54) min, and (2.44±0.17) min], with statistically significant differences (all P<0.05). In the observation group, the Vmean [(62.82±5.47) cm/s], Vmax [(87.94±9.78) cm/s], level of BDNF [(6.64±0.87) μg/L], and BI [(69.64±7.14) points] were higher than those in the control group [(58.62±5.34) cm/s, (84.14±8.66) cm/s, (5.03±0.82) μg/L, and (62.38±6.72) points], with statistically significant differences (all P<0.05). Conclusion　Clopidogrel combined with edaravone dexamphetamine is more effective in the treatment of ACI, which can effectively inhibit the inflammatory response and scavenge oxygen free radicals, thus improving the flow of blood in the brain, rapidly restoring the blood supply to the ischemic hemispheric zone, and contributing to the recovery of neurological function and enhancing the self-care ability, with higher safety.

Key words:

Acute cerebral infarction, Edaravone dexamphetamine, Clopidogrel, Inflammatory factors, Hemodynamics, Oxidative stress

文彤冯桂平王泽峰.

氯吡格雷联合依达拉奉右莰醇对急性脑梗死患者的疗效观察 [J]. 国际医药卫生导报, 2023, 29(9): 1280-1286.

Wen Tong, Feng Guiping, Wang Zefeng.

Effect of clopidogrel combined with edaravone dexamphetamine on patients with acute cerebral infarction [J]. International Medicine and Health Guidance News, 2023, 29(9): 1280-1286.

参考文献

[1] 张然,田浩林,王丽婷,等. 静脉溶栓及血管内治疗急性脑梗死的国内研究进展[J]. 中华全科医学,2020,18(11):1916-1920.DOI:10.16766/j.cnki.issn.1674-4152.001653.
[2] 刘建,陈昱灿,李俊鹏. 急性期脑梗死患者CT及MRI影像学特点分析[J]. 中国CT和MRI杂志,2019,17(5):18-21.DOI:10.3969/j.issn.1672-5131.2019.05.006.
[3] Pan Y, Elm JJ, Li H, et al. Outcomes associated with clopidogrel-aspirin use in minor stroke or transient ischemic attack: a pooled analysis of clopidogrel in high-risk patients with acute non-disabling cerebrovascular events (CHANCE) and platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trials[J].JAMA Neurol,2019,76(12):1466-1473.DOI:10.1001/jamaneurol.2019.2531.
[4] 王瑜,梁超,王宝爱,等. 依达拉奉治疗急性脑梗死的TLR4/NF-κB信号通路水平与脑血流量的相关性研究[J]. 脑与神经疾病杂志,2021,29(8):488-491.
[5] 张亚洁,王炎强,牟英峰,等. 依达拉奉右莰醇对脑缺血再灌注大鼠焦虑抑郁样行为的影响及机制[J]. 中华行为医学与脑科学杂志,2022,31(1):17-24.DOI:10.3760/cma.j.cn371468-20210602-00303.
[6] 中国老年医学学会急诊医学分会,中华医学会急诊医学分会卒中学组,中国卒中学会急救医学分会,等. 急性缺血性脑卒中急诊急救中国专家共识(2018)[J]. 临床急诊杂志,2018,19(6):351-359.DOI:10.13201/j.issn.1009-5918. 2018.06.001.
[7] Eskioglou E, Huchmandzadeh Millotte M, Amiguet M, et al. National institutes of health stroke scale zero strokes[J].Stroke,2018,49(12):3057-3059.DOI:10.1161/STROKEAHA.118.022517.
[8] 脑卒中患者临床神经功能缺损程度评分标准(1995)[J].中华神经科杂志,1996(6):62-64.
[9] 张雅静,张小兰,马延爱,等. Barthel指数量表应用于急性脑卒中患者生活能力测量的信度研究[J]. 中国护理管理,2007,7(5):30-32.DOI:10.3969/j.issn.1672-1756.2007. 05.011.
[10] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志,2018,51(9):666-682.DOI:10.3760/cma.j.issn.1006-7876.2018.09.004.
[11] Lv G, Wang GQ, Xia ZX, et al. Influences of blood lipids on the occurrence and prognosis of hemorrhagic transformation after acute cerebral infarction: a case-control study of 732 patients[J].Mil Med Res,2019,6(1):2.DOI:10.1186/s40779-019-0191-z.
[12] 肖俊锋,饶凯华,于晓明,等. 加味天麻钩藤饮对急性脑梗死患者(风痰瘀阻型)VEGF、 TIMP-1、EPCs、 NSE及高凝状态的影响[J]. 时珍国医国药,2021,32(6):1348-1351.DOI:10.3969/j.issn.1008-0805.2021.06.19.
[13] Aizawa Y, Nakai T, Saito Y, et al. Calcified amorphous tumor-induced acute cerebral infarction[J].Int Heart J,2018,59(1):240-242.DOI:10.1536/ihj.17-020.
[14] 姜敏,张娜,白立红,等. 丁苯酞联合尤尼泰对急性脑梗死患者炎症及氧化应激反应的影响[J]. 现代中西医结合杂志,2021,30(26):2923-2926.DOI:10.3969/j.issn.1008-8849. 2021.26.017.
[15] 刘文慧,李海军,崔琼. 依达拉奉联合阿替普酶治疗对急性脑梗死患者血液流变学及炎症因子的影响[J]. 中华保健医学杂志,2020,22(5):522-524.DOI:10.3969/j.issn.1674- 3245.2020.05.021.
[16] 夏辉,祁占宁,王飒,等. 急性脑梗死患者血浆Hcy、血管内皮功能和血流动力学的改变及意义[J]. 中南医学科学杂志,2019,47(3):311-314.DOI:10.15972/j.cnki.43-1509/r.2019.03.022.
[17] 陈兆耀,夏鑫,姚蓓蓓,等. 急性脑梗死病人阿替普酶溶栓后24 h内使用通脑饮治疗的安全性和有效性分析[J]. 中西医结合心脑血管病杂志,2020,18(13):2147-2149.DOI:10.12102/j.issn.1672-1349.2020.13.034.
[18] 龙章玲,胡晓. 阿司匹林和氯吡格雷在急性脑梗死中的应用进展[J]. 中国医药,2019,14(8):1262-1265.DOI:10.3760/j.issn.1673-4777.2019.08.036.
[19] 肖飞燕,张伟,周宏灏,等. 影响氯吡格雷疗效的基因多态性研究进展[J]. 中国现代应用药学,2016,33(3):375-380.DOI:10.13748/j.cnki.issn1007-7693.2016.03.029.
[20] 王倩倩,刘斌,郭娟. 依达拉奉右莰醇注射用浓溶液治疗急性脑梗死的疗效与安全性观察[J]. 中风与神经疾病杂志,2022,39(4):333-335.DOI:10.19845/j.cnki.zfysjjbzz.2022. 0084.
[21] 刘洁,胡小辉,龚道恺. 急性脑梗死患者外周血Th17、Treg、Th17/Treg及炎症因子的动态变化过程研究[J]. 临床神经病学杂志,2020,33(2):102-105.DOI:10.3969/j.issn.1004- 1648.2020.02.006.
[22] 李兴明,刘娟娟,陈俊斌,等. 复方脑肽节苷脂注射液对急性脑梗死的临床疗效及对患者Lp-PLA2 hs-CRP NSE水平的影响[J]. 河北医学,2020,26(3):393-397.DOI:10.3969/j.issn.1006-6233.2020.03.010.
[23] 刘浩,吴瑞杰,丁玉雪,等. 血清PTX3、Cav-1、hs-CRP与急性脑梗死患者病情及预后的关系研究[J]. 神经损伤与功能重建,2021,16(11):653-655.DOI:10.16780/j.cnki.sjssgncj.20201287.
[24] Deguchi I, Osada T, Takao M. Prescription status of oral anticoagulants in patients with acute cerebral infarction with non-valvular atrial fibrillation at the time of stroke onset[J].J Cardiol,2020,75(5):544-548.DOI:10.1016/j.jjcc.2019.11.002.
[25] 洪卫军,黄琴. 急性脑梗死患者血清ox-LDL、 Lp-PLA2水平变化及临床意义[J]. 中国医药导报,2019,16(5):72-75.
[26] 袁博博,舒庆,马冉冉,等. 急性脑梗死患者MDA、H2O2、SOD和ABTS的表达及临床意义[J]. 心脑血管病防治,2020,20(2):156-159.DOI:10.3969/j.issn.1009- 816x.2020.02.009.
[27] 夏月华,邱晓华. 丹红注射液联合重组组织型纤溶酶原激活剂溶栓治疗急性脑梗死的疗效及对血清氧化/抗氧化指标、炎症指标、神经功能指标的影响[J]. 实用医院临床杂志,2020,17(6):193-196.DOI:10.3969/j.issn.1672-6170. 2020.06.057.
[28] 夏宪军,鲍正社. 依达拉奉右莰醇对急性脑梗死患者神经功能、氧化应激及炎性因子的影响[J]. 湖南师范大学学报(医学版),2022,19(2):133-136.DOI:10.3969/j.issn.1673-016X.2022.02.037.